Objective: To investigate seizure outcomes and their relationships to genotype and functional abilities in individuals with the cyclin-dependent kinase-like-5 (CDKL5) disorder.
as a benchmark in randomized clinical trials investigating efficacy of antiepileptic drugs. Using data from an ongoing international CDKL5 patient registry, 13 populated primarily by parents about their children, we have demonstrated variability of attainment of developmental milestones and some relationships with genotype. Building on this work, the current study investigated seizure outcomes in individuals with the CDKL5 disorder and relationships with genotype, walking, and expressive communication skills.
METHODS Established in 2012, the International CDKL5 Disorder Database collects information from families/caregivers of a child with the CDKL5 disorder through completion of online or paper questionnaires. 13 As of January 2016, data on 241 individuals were recorded in the Database. Cases were included in this study if the CDKL5 variant was considered to be pathogenic and information on epilepsy had been provided.
As previously described, 13 CDKL5 mutations were grouped according to predicted structural and functional consequences. The groups were (1) variants resulting in no functional protein (including variants causing loss of the functional components in the catalytic domain before amino acid [aa] 172 and full gene deletions), (2) missense/in-frame variants within the catalytic domain (includes missense variants within the protein's kinase active region or in-frame variants), (3) truncating variants located between aa172 and aa781 (includes any variants resulting in a truncation such as nonsense or frameshift variants potentially resulting in maintaining kinase activity but loss of the C-terminal region), and (4) truncating variants occurring after aa781 (maintains kinase activity and the majority of the C-terminal region). Other mutations of unknown significance (e.g., duplication) were not included in the analysis. Based on appropriate developmental milestones for this disorder and the age distribution of our sample, age at ascertainment was categorized as less than 1.5 years, 1.5-6 years, 7-12 years, or more than 12 years.
Families/caregivers were asked to report on concerns during the neonatal period. Age at seizure onset was the age at first observation of seizures. Current seizure rate was the average number of seizures per day at the time of ascertainment and, for descriptive purposes, was categorized as seizure-free (for at least 2 months), monthly, weekly, 1 to 5 a day, or more than 5 a day. Families/ caregivers also reported the longest prior seizure-free ("honeymoon") period of more than 2 months including start and end age. Monotherapy was defined as the current use of any single antiepileptic drug (AED) and polytherapy was concurrent use of 2 or more prescribed AEDs at the time of ascertainment. Ever been treated with steroids/ACTH and current use of nonpharmaceutical therapies such as ketogenic diet and vagal nerve stimulation (VNS) were both coded as either yes or no.
Families/carers were asked to indicate the current level of assistance required by their child to stand for 20 seconds or walk for 10 steps, coded as needing no assistance (independent), needing some assistance (assisted), or unable to complete/needing maximal assistance (unable). Responses were then dichotomized into yes (independent and assisted) or no (unable). The highest level of expressive communication was derived from responses to questions about the communication the child used to convey refusal or requesting an object or experience. Responses were Table 1 Characteristics of individuals with pathogenic CDKL5 mutation by epilepsy status (n 5 172) categorized as simple communication including body language (e.g., twisting body or kicking), early sounds (e.g., crying, screaming, or grunting), facial expression (e.g., grimacing or frowning), and simple gestures (e.g., pushing away object or holding hands); complex gestures, concrete symbols, and vocalizations (e.g., shaking heads, rejecting/selecting drawings, or pointing at objects); or spoken language and abstract symbols such as signing "yes" or "no." Individuals of age below 2 years were excluded from the description of motor and communication skills to avoid scoring children on tasks too complex for their chronological age.
Standard protocol approvals, registrations, and patient consents. The study was approved by the University of Western Australia Human Research Ethics Committee (reference # RA/4/ 1/5024).
Statistical analysis. Descriptive statistics were used to summarize the characteristics of individuals in the study. The Kaplan-Meier method was used to estimate the probability of and median age at first seizure and the log-rank test was used to test for differences in age at seizure onset by mutation group. Fisher exact test of independence was used to evaluate whether the prevalence of early neonatal concerns varied with age at seizure onset, and Kruskal-Wallis equality-of-populations rank test to investigate the duration of honeymoon period by mutation group. Negative binomial regression was used to model the relationships between current seizure rate (expressed as count data) and mutation group, ever been treated with steroids/ ACTH, an interaction term of both mutation group and ever been treated with steroids/ACTH, walking, and expressive communication skills. Crude estimates, in addition to those adjusted for potential confounders, such as sex, duration of epilepsy, presence of a honeymoon period, antiepileptic polytherapy, and use of ketogenic diet and VNS, were reported. Data were assumed missing at random and only complete data were analyzed in the model. All statistical analyses were conducted using Stata version 14 (StataCorp LP, College Station, TX).
RESULTS
By January 2016, 192 individuals registered with the International CDKL5 Disorder Database had a pathogenic CDKL5 mutation. The median age at ascertainment was 5 years 1 month (range 3 months-33 years 10 months) and 84.9% (n 5 163) were female. Of these, 172 families had responded to the questionnaire section related to epilepsy and the characteristics of their child are shown in table 1. Three individuals never developed epilepsy and their clinical details are presented in table 2. For those with reported epilepsy (n 5 169), the majority (87.0%) were female and about half (51.5%) were living in the United States. Nearly half (45.6%) were between 1.5 and 6 years of age at ascertainment. The most common mutation groups were truncating mutations between aa172 and aa781 (30.8%), followed by no functional protein (29.6%) and missense/in-frame mutations within catalytic domain (25.4%). In the children who developed epilepsy, difficulty feeding (27.7%, 46/166), prolonged sleeping time (19.4%, 32/165), and floppiness when moved or handled (17.7%, 29/164) were the most commonly reported early concerns within 48 hours of birth. These concerns were also noted by families/carers of the 3 children with no history of epilepsy. By 1 month of age, 31.5% (52/165) of the families whose children developed epilepsy reported that their child gave strange stares or looks. Just over a quarter (27.1%, 45/166) also reported that their children cried more than expected. The prevalence of floppiness had increased to 30.1% (50/166) while difficulty feeding was 24.1% (40/166). At ascertainment, the majority of children with epilepsy were unable to stand (54.2%, 71/131) or walk (64.6%, 84/130), and less than a third (29.8%, 39/131) had the simplest level of communication. On the other Gave strange stares or looks (n 5 168) 52 (31.5) 0
Abbreviations: aa 5 amino acid; AED 5 antiepileptic drug.
Percentages have been rounded and may not total to 100%. a Limited to individuals at least 2 years of age at ascertainment. hand, more children without epilepsy were able to stand and walk independently, and communicate using complex gestures or spoken language (table 1). The median age at seizure onset was 6 weeks (range 1 week-1.5 years) and did not vary by mutation group (log-rank test x 2 [3] 5 4.44, p 5 0.218) (figure 1). Around one-third (33.8%, n 5 48) of the individuals with epilepsy were reported to have had infantile spasms (table 1) . Seizures developing within the first month of life appeared to be associated with early concerns such as prolonged sleep and strange stares as reported over the same period (table 3) . Of the 169 individuals with epilepsy, 163 (96.4%) families provided information on periods of seizure freedom, and 71 (43.6%) of these families reported their child had ever been seizure-free for more than 2 months. Of these, a honeymoon period with a median onset of 2 years (range 2 months-11 years) and a median duration of 6 months (range 2.5 months-6 years) was recorded for 52/70 (74%) and 59/70 (84%) individuals, respectively. Duration of honeymoon period did not vary by mutation group (Kruskal-Wallis equality-of-populations rank test x 2 [3] 5 3.673, p 5 0.299). The age at seizure onset, age at ascertainment, and when available, age at the start and end of seizure-free period of the 169 individuals with epilepsy history are illustrated in figure e-1 at Neurology.org.
The median seizure rate was 2 per day (range 0-20 per day). The majority of children (56.2%) were reported to have, on average, 1 to 5 seizures per day. Around one-fifth (20.9%) had less than one seizure per day and a smaller group (15.0%) had more than 5 seizures a day. Fewer than one-tenth (7.8%, n 5 12) of individuals had not experienced any seizures in the 6 months prior to ascertainment and their clinical details are presented in table 2. For the 30 individuals who were younger than 2 years, 10 children had no functional protein mutation and most (80%) had 1 to 5 seizures a day and 2 had monthly seizures. In those with missense/in-frame mutations within catalytic domain (n 5 9), 8 individuals had current seizures (weekly n 5 2, 1-5/day n 5 5, .5/day n 5 1) and 1 had no current seizures. All children with truncating mutations between aa172 and aa781 had current seizures (monthly n 5 1, weekly n 5 2, 1-5/day n 5 4, .5/day n 5 3). Only one individual had a truncating mutation after aa781 and no current seizure was reported.
In those aged 2 years and over, and after adjusting for walking ability and confounders, the seizure rate was lower in those with missense/in-frame mutations (incidence rate ratio [IRR] 0.60; 95% confidence interval [CI] 0.35-1.02) and truncating mutations between aa172 and aa781 (IRR 0.57; 95% CI 0.35-0.93) compared to individuals with no functional protein (table 4) . Similarly, after controlling for communication level and confounders, the rate of seizures was lower (IRR 0.60; 95% CI, 0.36-0.90) in those with a truncating mutations between aa172 and aa781 when compared with those with no functional protein. Regarding functional abilities, there was evidence to suggest that being able to walk assisted or independently was associated with a lower rate of current seizures when compared to those unable to walk (IRR 0.62; 95% CI 0.39-0.99) after adjusting for genotype. Likewise, individuals who were able to use spoken language had a lower rate of seizures when compared to those who used simple communication skills (IRR 0.48; 95% CI 0.23-1.02) (table 4).
The top 10 AEDs, out of the 29 that were reported, are shown in table e-1. Clobazam was the most commonly used AED, followed by valproate, topiramate, levetiracetam, and vigabatrin. Ketogenic diet (24 responses) and VNS (26 responses) were also used. In the United States, topiramate and clonazepam were frequently prescribed, while valproate, vigabatrin, rufinamide, and zonisamide were more commonly used in countries outside the United States. Close to one-third of individuals with epilepsy (30.5%, n 5 43) were previously treated with steroids/ACTH. At a median age at questionnaire completion of 5 years (n 5 108, range 1-33 years), the seizure rate was higher in those treated with steroids compared with those who never received the treatment irrespective of adjusting or not for confounders (table e-2). The association appeared to be similar between those with and without a history of infantile spasms, and in those with infantile spasms mutation Estimated probability of seizure onset by mutation group among individuals with a pathogenic CDKL5 mutation (n 5 158)
Kaplan-Meier estimates of probability of seizure onset by mutation group among individuals with a pathogenic CDKL5 mutation. Twelve individuals in the genotype subcategory "mutation not grouped" were excluded from the analysis.
group also affected the risk (table e-3) . Among individuals who were diagnosed with infantile spasms (n 5 41, median age at questionnaire completion 6 years, range 1-29 years), past treatment with steroids was associated with a more than 2-fold increase in current rate of seizure in those with missense/inframe mutations within catalytic domain and truncations between aa172 and aa781 (table e-4). However, such relationship was not observed in those with nonfunctional protein mutations.
DISCUSSION Seizures are the most common clinical feature in the CDKL5 disorder. This article describes the onset and frequency of seizures in a unique, large sample of affected individuals. The size of our sample has provided novel information on relationships between seizure outcome and both genotype and functional abilities taking into account the influences of confounding variables. This study has characterized the features of the honeymoon period commonly observed in this disorder and demonstrated that, although uncommon, seizure freedom can be attained. Six weeks was the median age at seizure onset, 3 although age at onset ranged from 1 to 78 weeks. Seizures occurred slightly earlier when there were other neonatal concerns but we could not identify any relationship between age at onset and genotype. However, compared to other mutation groups and after adjustment for functional ability, those individuals with no functional protein were more likely to have frequent seizures, the protective effect being greatest for those with a truncating mutation between aa172 and aa781. The underlying mechanism for these findings remains unclear, possibly representing a different trajectory for this group or perhaps capacity for greater responsiveness biologically to AEDs.
We also found a reduction in seizure frequency in those with a truncation after aa781 but this reduction was less evident perhaps because of the smaller case numbers overall.
There has been varying reports of the short-term efficacy of steroids in CDKL5-related epilepsy and for childhood epilepsy in general. 14, 15 Overall our results show that refractory epilepsy is not uncommon in CDKL5 disorder, and perhaps use of steroids was an indicator of difficult to treat epilepsy. Alternatively, AEDs can worsen seizures 16 and it is plausible that steroids could worsen seizures in specific CDKL5 genotypes but the modest numbers in our subgroup analyses on use of steroids need to be borne in mind. Further research on the role of steroids in the early and later stages of this disorder is needed, ideally in prospective trials.
Better functional abilities were also associated with less frequent seizures after accounting for mutation group, possibly reflecting better overall neurologic function. These relationships are, however, complex because we previously found that the mutation group with a truncation after aa781 was more likely to acquire developmental skills with better functional abilities. 13 Although the CDKL5 disorder is often labeled as an "epileptic encephalopathy defined by cognitive involvement due to ictal and/ or inter-ictal activities," a recent multinational study considered it as a "genetic epilepsy with encephalopathy." 14 The debate on this matter continues. Of interest are 3 patients who never had seizures, which is unusual for the CDKL5 disorder. This raises the question of the pathogenicity of their CDKL5 variations. Given that the p.Met63Cysfs*13 variation causes a frameshift mutation that completely disrupts the catalytic domain, it would be assumed to be a loss of function mutation. Regarding the 2 missense variations, in silico analyses suggest that they are both likely to be pathogenic (table e-5). Therefore, we reaffirm that epilepsy is not an absolute component of the CDKL5 disorder. We also notice that these individuals had better functional abilities. When these data are combined with the number of patients in our cohort who were seizure-free but with varying functional abilities, it raises the question of whether less severe epilepsy or better control of epilepsy allows for greater function or not.
A honeymoon period with seizure cessation for a period of time has previously been described in the CDKL5 disorder 10 and our study has further characterized its features. As reported by just over a third of families, this could last up to 72 months with a median duration of 6 months and, after adjustment for functional ability, was predictive of reduced seizure frequency in the longer term. We also catalogued the large number of AEDs used and identified Table 3 Frequency distribution of early parental concerns within the first month following birth by seizure onset age in individuals with pathogenic CDKL5 mutation and epilepsy (n 5 169)
No. some differences in their use in the United States compared with elsewhere. The majority of studies to date relating to epilepsy in the CDKL5 disorder have been clinical studies with small case numbers of less than 10 patients. [4] [5] [6] [7] [8] [9] [10] [11] [12] The largest 2 have been an early French case series, 10 and a recent multinational study with 39 patient contributions from 27 clinicians in 11 countries. 14 The first described the clinical and EEG trajectory of epilepsy in 12 patients whose median age at onset was 4 weeks, ranging from 1 to 10 weeks. 10 Over half of the 12 patients were seizure-free, in contrast to a much lower percentage in our more statistically powerful study, and any genotype-phenotype correlations were only based on 6 patients. The second study collated the experiences of 39 patients with the CDKL5 disorder with respect to response of seizure frequency to AEDs including the ketogenic diet. 14 In line with our results, only 2 of 39 patients remained seizure-free after 12 months follow-up but no genotype data were presented.
Large sample sizes are mandatory for investigation of genotype and other relationships in rare disorders especially in the case of CDKL5 where, unlike Rett syndrome, 17 the majority of mutations are unique. Our current categorization of mutations was based on predicted structural and functional consequences, 13 but it may not be optimal. Although our database comprises the largest known data collection on the CDKL5 disorder, there may still be some concerns about parent report, but such data are wellaccepted in clinical practice and in clinical trials. 14 However, our study is likely skewed towards families of higher socioeconomic status as genetic testing is required for diagnosis.
This observational study adds to the understanding of epilepsy in the CDKL5 disorder. Investigating factors that may predict either better or worse outcomes is essential in our quest to improve management and quality of life for these patients and their families.
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